查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1882974

败血症抗生素市场规模、占有率、成长及全球产业分析：按类型、应用和地区划分的洞察与预测（2024-2032 年）

Septicemia Antibiotics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 160 Pages | 商品交期: 请询问到货日

价格

败血症抗生素市场成长因素

由于全球细菌感染和血液相关併发症的增加，全球脓毒症抗生素市场持续扩张。根据本报告，预计该市场在 2024 年将达到 26.1 亿美元，在 2025 年将达到 26.7 亿美元。预计到 2032 年，该市场将成长至 32.7 亿美元，预测期内复合年增长率 (CAGR) 为 2.9%。北美在 2024 年占了 44.06% 的主导市场占有率，这得益于其强大的医疗保健基础设施、较高的公众意识和大量的研发投入。

败血症（血液中毒）是指感染性病原体进入血液，引起严重的全身性炎症，并可能发展为败血症。随着金黄色葡萄球菌、肺炎链球菌和大肠桿菌感染病例的持续增加，对高效抗生素的需求也不断增加。院内感染、术后併发症、泌尿道感染、重症病患数量的增加，都是促使败血症的重要因素。根据Science Direct 2025年6月的一项研究，在1085名住院患者中，16.7%患有细菌感染，这凸显了促使脓毒症的疾病的普遍流行，并进一步强化了对抗生素治疗的需求。

市场动态

成长因素

严重细菌感染（尤其是在儿童和老年族群）发病率的上升，仍然是市场成长的主要推动力。这些年龄层的免疫系统较弱，更容易发生血液感染。尿路感染是脓毒症的主要原因之一，其发生率在全球范围内也在上升。根据泌尿科护理基金会（2022年11月）的数据，12%的男性和60%的女性一生中至少会经历一次尿路感染，这增加了血液併发症的风险，并推动了对速效抗生素的需求。

限制因子

市场成长的最大障碍是抗菌素抗药性（AMR）的快速成长。随着细菌的演化，它们会对常用抗生素产生抗药性，从而降低治疗效果。 AMR会促使住院时间延长、死亡率升高和治疗成本上升。美国国家生物技术资讯中心（2021年3月）报告称，泌尿道感染中AMR的盛行率已达到53%，这凸显了传统抗生素的局限性日益扩大，以及它们在治疗败血症方面的疗效下降。

机会

随着抗药性感染的快速增加，开发新型抗生素已成为全球优先事项。这为製药公司、研究机构和政府支持的创新项目带来了巨大的成长机会。 CARB-X计划和抗菌药物抗药性行动基金正在加速抗生素的研究。 2024年1月，UTILITY Therapeutics公司宣布其用于治疗泌尿道感染的抗生素PIVYA的新药申请（NDA）已获受理，该药物由抗菌药物抗药性行动基金资助。这表明，各方正大力投资于能够降低败血症风险的下一代疗法。

挑战

败血症的诊断仍然十分复杂。由于缺乏普遍认可的检测方法，诊断主要依赖临床症状和多项检查结果。根据MedPark医院的报告显示，诊断通常需要进行血液培养、肾功能检查、X光检查、CT扫描和MRI检查。这种复杂性可能促使治疗延误、增加死亡风险，并阻碍及时使用抗生素。

市场趋势

人工智慧驱动的诊断技术和药物研发正成为变革性趋势。人工智慧工具能够提高细菌感染的快速检测率，预测抗菌药物抗药性（AMR）模式，并加速新型候选抗生素的发现。根据2025年3月 "NPJ Journal" 的报告，人工智慧在传染病诊断、AMR监测和抗生素药物研发的应用预计将显着增加，有助于提高败血症治疗的准确性。

细分市场洞察

依药物类别

截至2024年，青霉素类药物因其低毒性、价格实惠且对常见革兰氏阳性菌有效而占市场主导地位。

头孢菌素类药物凭藉其广谱抗菌活性，预计将占相当大的市场占有率，并实现最快增长。头孢地洛（Cefiderocol）于 2019 年获得美国 FDA 批准，因其在治疗泌尿道感染 (UTI) 和肺炎（败血症的两大主要病因）方面的疗效而备受关注。

依给药途径

由于起效迅速，肠外抗生素占了最大的市场占有率，这在紧急情况下尤其重要。注射盐酸万古霉素是一种广泛用于治疗败血症的肠外给药药物。

口服药物因其方便性和价格优势，在轻症患者中保持了稳定的市场占有率。

按分销管道

由于住院的重症感染患者数量不断增加，预计到 2024 年，医院药房将占市场主导地位。提供便利治疗方案的零售药局也占了相当大的市场。

区域展望

由于感染意识高涨和研发投入强劲，北美市场规模预计在2024年达到11.5亿美元。美国在该地区处于领先地位，这主要得益于其较高的脓毒症发病率以及人工智慧在诊断领域的先进应用。

根据欧洲疾病预防控制中心（ECDC）2024年的数据，欧洲占医院感染病例的很大一部分，每年病例达430万例。

亚太地区是成长最快的地区，主要受泌尿道感染（UTI）盛行率上升和血流感染病例增加的推动。 2014年至2019年间，中国的血流感染病例增加了73%。

拉丁美洲和中东/非洲地区由于传染病负担加重和医疗保健服务可近性的提高，正经历稳定成长。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：主要发现

  • 败血症感染的流行病学
  • 主要国家和地区的报销情况
  • 主要公司的研发管线分析
  • 主要公司的新产品发布
  • 主要产业趋势，包括併购和合作

第五章：全球败血症抗生素市场分析、洞察与预测（2019-2032）

  • 按药物类别划分的市场分析、洞察与预测
    • 青霉素类
    • 头孢菌素类
    • 氟喹诺酮类
    • 醣肽类
    • 其他
  • 按给药途径划分的市场分析、洞察与预测
    • 口服
    • 注射给药
  • 按销售管道划分的市场分析、洞察与预测
    • 医院药房
    • 零售药房
    • 线上药房
  • 按地区划分的市场分析、洞察与预测
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章 北美败血症抗生素市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 美国
    • 加拿大

第七章 欧洲败血症抗生素市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 斯堪的纳维亚
    • 欧洲其他地区

第八章 亚太地区败血症抗生素市场分析、洞察与预测2019-2032

  • 依国家划分
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章：拉丁美洲败血症抗生素市场分析、洞察与预测，2019-2032

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第十章：中东与非洲败血症抗生素市场分析、洞察与预测，2019-2032

  • 依国家划分
    • 海湾合作委员会
    • 南非
    • 中东其他地区以及非洲

第十一章 竞争分析

  • 全球市占率分析（2024 年）
  • 公司简介
  • 拜耳股份公司
  • STERIS HEALTHCARE PVT LTD
  • AdvaCare Pharma
  • Intelicure Lifesciences
  • Cipla
  • Mylan Institutional LLC
Product Code: FBI113752

Growth Factors of septicemia antibiotics Market

The global septicemia antibiotics market continues to expand as bacterial infections and bloodstream-related complications increase worldwide. According to the report, the market was valued at USD 2.61 billion in 2024, is projected to reach USD 2.67 billion in 2025, and is forecast to grow to USD 3.27 billion by 2032, reflecting a CAGR of 2.9% during the forecast period. In 2024, North America held the dominant share of 44.06%, supported by strong healthcare infrastructure, high awareness, and significant R&D spending.

Septicemia, or blood poisoning, occurs when infectious pathogens enter the bloodstream and trigger severe systemic inflammation that may progress to sepsis. As infections caused by Staphylococcus aureus, Streptococcus pneumoniae, and E. coli continue to rise, demand for effective antibiotics intensifies. Hospital-acquired infections, post-surgical complications, urinary tract infections, and a growing population of critically ill patients contribute significantly to septicemia cases. A June 2025 Science Direct study reported that 16.7% of 1,085 hospitalized patients had bacterial infections, highlighting the wide prevalence of conditions that can lead to septicemia and strengthening the need for antibiotic treatment.

Market Dynamics

Drivers

A rising incidence of severe bacterial infections, particularly among pediatric and geriatric populations, remains the key driver for market growth. These age groups have weaker immune systems and are more susceptible to bloodstream infections. Urinary tract infections-a major contributor to septicemia-are also increasing globally. According to the Urology Care Foundation (November 2022), 12% of men and 60% of women will experience at least one UTI in their lifetime, elevating the risk of bloodstream complications and the demand for fast-acting antibiotics.

Restraints

The biggest barrier to market growth is the sharp rise in antimicrobial resistance (AMR). As bacteria evolve, they develop resistance to commonly used antibiotics, reducing treatment effectiveness. AMR drives longer hospital stays, higher mortality rates, and elevated treatment costs. The National Center for Biotechnology Information (March 2021) reported 53% AMR prevalence in UTIs, highlighting the growing limitations of traditional antibiotics and their diminishing impact on septicemia treatment.

Opportunities

With antibiotic-resistant infections rising sharply, there is an urgent global need for novel antibacterial drugs. This offers significant growth opportunities for pharmaceutical companies, research institutions, and government-supported innovation programs. The CARB-X initiative and AMR Action Fund are accelerating antibiotic research. In January 2024, UTILITY Therapeutics announced acceptance of its NDA for PIVYA, an antibiotic for UTI management, backed by AMR Action Fund financing-demonstrating strong investment in next-generation therapies that can also reduce septicemia risk.

Challenges

Diagnosing septicemia remains complex, as there is no universally accepted test and diagnosis relies heavily on clinical presentation and multiple laboratory assessments. MedPark Hospital reports that diagnosis often requires blood cultures, kidney function tests, X-rays, CT scans, MRIs, and more. These complexities can delay treatment, increasing the risk of mortality and limiting timely adoption of antibiotics.

Market Trends

AI-driven diagnostics and drug discovery are emerging as transformative trends. AI tools improve rapid detection of bacterial infections, predict AMR patterns, and accelerate identification of new antibiotic candidates. According to the NPJ Journal (March 2025), AI adoption is expected to rise significantly for infection diagnostics, AMR surveillance, and antibiotic discovery-improving precision in septicemia treatment.

Segmentation Insights

By Drug Class

Penicillin dominated the market in 2024 due to its low toxicity, affordability, and effectiveness against common gram-positive bacteria.

Cephalosporins held a significant share and are expected to grow fastest due to broad-spectrum activity. Cefiderocol, approved by the U.S. FDA in 2019, is noted for its effectiveness in treating UTIs and pneumonia-major causes of septicemia.

By Route of Administration

Parenteral antibiotics accounted for the largest market share, driven by rapid onset of action required in emergency settings. Injectable Vancomycin Hydrochloride is a commonly used parenteral agent for septicemia.

The oral segment retained steady adoption due to convenience and affordability in milder cases.

By Distribution Channel

Hospital pharmacies dominated in 2024, supported by rising hospital admissions for severe infections. Retail pharmacies also held a significant share, offering accessible treatment options.

Regional Outlook

In 2024, North America generated USD 1.15 billion, driven by high infection awareness and strong R&D investments. The U.S. leads the region due to high septicemia incidence and advanced adoption of AI for diagnostics.

Europe holds a significant share, with 4.3 million annual hospital-acquired infection cases, according to ECDC 2024 data.

Asia Pacific is the fastest-growing region, driven by rising UTI prevalence and increasing bloodstream infections-China saw a 73% rise in BSI cases from 2014 to 2019.

Latin America and Middle East & Africa show steady growth due to rising infectious disease burden and improving healthcare access.

Conclusion

Growing from USD 2.61 billion in 2024 to USD 3.27 billion by 2032, the septicemia antibiotics market will remain vital as global infection rates rise, research investment accelerates, and new antibiotic products enter the market.

Segmentation By Drug Class

  • Penicillin
  • Cephalosporin
  • Fluoroquinolones
  • Glycopeptides
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Geography

  • North America (By Drug Class, Route of Administration, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Epidemiology of Septicemia Infection
  • 4.2. Reimbursement Scenario, By Key Countries/Regions
  • 4.3. Pipeline Analysis, By Key Players
  • 4.4. New Product Launches, By Key Players
  • 4.5. Key Industry Developments Such as Mergers, Acquisitions, and Partnerships

5. Global Septicemia Antibiotics Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. Penicillin
    • 5.1.2. Cephalosporin
    • 5.1.3. Fluoroquinolones
    • 5.1.4. Glycopeptides
    • 5.1.5. Others
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Oral
    • 5.2.2. Parenteral
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital Pharmacy
    • 5.3.2. Retail Pharmacy
    • 5.3.3. Online Pharmacy
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Septicemia Antibiotics Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. Penicillin
    • 6.1.2. Cephalosporin
    • 6.1.3. Fluoroquinolones
    • 6.1.4. Glycopeptides
    • 6.1.5. Others
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Oral
    • 6.2.2. Parenteral
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospital Pharmacy
    • 6.3.2. Retail Pharmacy
    • 6.3.3. Online Pharmacy
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Septicemia Antibiotics Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. Penicillin
    • 7.1.2. Cephalosporin
    • 7.1.3. Fluoroquinolones
    • 7.1.4. Glycopeptides
    • 7.1.5. Others
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Oral
    • 7.2.2. Parenteral
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospital Pharmacy
    • 7.3.2. Retail Pharmacy
    • 7.3.3. Online Pharmacy
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Septicemia Antibiotics Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. Penicillin
    • 8.1.2. Cephalosporin
    • 8.1.3. Fluoroquinolones
    • 8.1.4. Glycopeptides
    • 8.1.5. Others
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Oral
    • 8.2.2. Parenteral
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospital Pharmacy
    • 8.3.2. Retail Pharmacy
    • 8.3.3. Online Pharmacy
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Septicemia Antibiotics Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. Penicillin
    • 9.1.2. Cephalosporin
    • 9.1.3. Fluoroquinolones
    • 9.1.4. Glycopeptides
    • 9.1.5. Others
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Oral
    • 9.2.2. Parenteral
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospital Pharmacy
    • 9.3.2. Retail Pharmacy
    • 9.3.3. Online Pharmacy
  • 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Septicemia Antibiotics Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Drug Class
    • 10.1.1. Penicillin
    • 10.1.2. Cephalosporin
    • 10.1.3. Fluoroquinolones
    • 10.1.4. Glycopeptides
    • 10.1.5. Others
  • 10.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.2.1. Oral
    • 10.2.2. Parenteral
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Hospital Pharmacy
    • 10.3.2. Retail Pharmacy
    • 10.3.3. Online Pharmacy
  • 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability))
    • 11.2.1. Bayer AG
    • 11.2.2. STERIS HEALTHCARE PVT LTD
    • 11.2.3. AdvaCare Pharma
    • 11.2.4. Intelicure Lifesciences
    • 11.2.5. Cipla
    • 11.2.6. Mylan Institutional LLC

List of Tables

  • Table 1: Global Septicemia Antibiotics Market Revenue (USD billion) Forecast, By Drug Class, 2019-2032
  • Table 2: Global Septicemia Antibiotics Market Revenue (USD billion) Forecast, By Route of Administration, 2019-2032
  • Table 3: Global Septicemia Antibiotics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 4: Global Septicemia Antibiotics Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 5: North America Septicemia Antibiotics Market Revenue (USD billion) Forecast, By Drug Class, 2019-2032
  • Table 6: North America Septicemia Antibiotics Market Revenue (USD billion) Forecast, By Route of Administration, 2019-2032
  • Table 7: North America Septicemia Antibiotics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 8: North America Septicemia Antibiotics Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 9: Europe Septicemia Antibiotics Market Revenue (USD billion) Forecast, By Drug Class, 2019-2032
  • Table 10: Europe Septicemia Antibiotics Market Revenue (USD billion) Forecast, By Route of Administration, 2019-2032
  • Table 11: Europe Septicemia Antibiotics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 12: Europe Septicemia Antibiotics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 13: Asia Pacific Septicemia Antibiotics Market Revenue (USD billion) Forecast, By Drug Class, 2019-2032
  • Table 14: Asia Pacific Septicemia Antibiotics Market Revenue (USD billion) Forecast, By Route of Administration, 2019-2032
  • Table 15: Asia Pacific Septicemia Antibiotics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 16: Asia Pacific Septicemia Antibiotics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 17: Latin America Septicemia Antibiotics Market Revenue (USD billion) Forecast, By Drug Class, 2019-2032
  • Table 18: Latin America Septicemia Antibiotics Market Revenue (USD billion) Forecast, By Route of Administration, 2019-2032
  • Table 19: Latin America Septicemia Antibiotics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 20: Latin America Septicemia Antibiotics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 21: Middle East & Africa Septicemia Antibiotics Market Revenue (USD billion) Forecast, By Drug Class, 2019-2032
  • Table 22: Middle East & Africa Septicemia Antibiotics Market Revenue (USD billion) Forecast, By Route of Administration, 2019-2032
  • Table 23: Middle East & Africa Septicemia Antibiotics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 24: Middle East & Africa Septicemia Antibiotics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Global Septicemia Antibiotics Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global Septicemia Antibiotics Market Value Share (%), By Drug Class, 2024 & 2032
  • Figure 3: Global Septicemia Antibiotics Market Value Share (%), By Route of Administration, 2024 & 2032
  • Figure 4: Global Septicemia Antibiotics Market Value Share (%), by Distribution Channel, 2024 & 2032
  • Figure 5: Global Septicemia Antibiotics Market Value Share (%), by Region, 2024 & 2032
  • Figure 6: North America Septicemia Antibiotics Market Value (USD billion), By Drug Class, 2024 & 2032
  • Figure 7: North America Septicemia Antibiotics Market Value Share (%), By Drug Class, 2024
  • Figure 8: North America Septicemia Antibiotics Market Value (USD billion), By Route of Administration, 2024 & 2032
  • Figure 9: North America Septicemia Antibiotics Market Value Share (%), By Route of Administration, 2024
  • Figure 10: North America Septicemia Antibiotics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 11: North America Septicemia Antibiotics Market Value Share (%), by Distribution Channel, 2024
  • Figure 12: North America Septicemia Antibiotics Market Value (USD billion), By Country, 2024 & 2032
  • Figure 13: North America Septicemia Antibiotics Market Value Share (%), By Country, 2024
  • Figure 14: Europe Septicemia Antibiotics Market Value (USD billion), By Drug Class, 2024 & 2032
  • Figure 15: Europe Septicemia Antibiotics Market Value Share (%), By Drug Class, 2024
  • Figure 16: Europe Septicemia Antibiotics Market Value (USD billion), By Route of Administration, 2024 & 2032
  • Figure 17: Europe Septicemia Antibiotics Market Value Share (%), By Route of Administration, 2024
  • Figure 18: Europe Septicemia Antibiotics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 19: Europe Septicemia Antibiotics Market Value Share (%), by Distribution Channel, 2024
  • Figure 20: Europe Septicemia Antibiotics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 21: Europe Septicemia Antibiotics Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 22: Asia Pacific Septicemia Antibiotics Market Value (USD billion), By Drug Class, 2024 & 2032
  • Figure 23: Asia Pacific Septicemia Antibiotics Market Value Share (%), By Drug Class, 2024
  • Figure 24: Asia Pacific Septicemia Antibiotics Market Value (USD billion), By Route of Administration, 2024 & 2032
  • Figure 25: Asia Pacific Septicemia Antibiotics Market Value Share (%), By Route of Administration, 2024
  • Figure 26: Asia Pacific Septicemia Antibiotics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 27: Asia Pacific Septicemia Antibiotics Market Value Share (%), by Distribution Channel, 2024
  • Figure 28: Asia Pacific Septicemia Antibiotics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 29: Asia Pacific Septicemia Antibiotics Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 30: Latin America Septicemia Antibiotics Market Value (USD billion), By Drug Class, 2024 & 2032
  • Figure 31: Latin America Septicemia Antibiotics Market Value Share (%), By Drug Class, 2024
  • Figure 32: Latin America Septicemia Antibiotics Market Value (USD billion), By Route of Administration, 2024 & 2032
  • Figure 33: Latin America Septicemia Antibiotics Market Value Share (%), By Route of Administration, 2024
  • Figure 34: Latin America Septicemia Antibiotics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 35: Latin America Septicemia Antibiotics Market Value Share (%), by Distribution Channel, 2024
  • Figure 36: Latin America Septicemia Antibiotics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 37: Latin America Septicemia Antibiotics Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 38: Middle East & Africa Septicemia Antibiotics Market Value (USD billion), By Drug Class, 2024 & 2032
  • Figure 39: Middle East & Africa Septicemia Antibiotics Market Value Share (%), By Drug Class, 2024
  • Figure 40: Middle East & Africa Septicemia Antibiotics Market Value (USD billion), By Route of Administration, 2024 & 2032
  • Figure 41: Middle East & Africa Septicemia Antibiotics Market Value Share (%), By Route of Administration, 2024
  • Figure 42: Middle East & Africa Septicemia Antibiotics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 43: Middle East & Africa Septicemia Antibiotics Market Value Share (%), by Distribution Channel, 2024
  • Figure 44: Middle East & Africa Septicemia Antibiotics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 45: Middle East & Africa Septicemia Antibiotics Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 46: Global Septicemia Antibiotics Market Share (%), By Company, 2024